Untitled

Solomkin, Joseph S.; Yellin, Albert E.; Rotstein, Ori D.; Christou, Nicolas V.; Dellinger, E. Patchen; Tellado, Jose M.; Malafaia, Osvaldo; Fernández, Álvaro F.; Choe, Kyuran A.; Carides, Alexandra D.; Satishchandran, Vilas; Teppler, Hedy; Group, the Protocol 017 Study

doi:10.1097/00000658-200302000-00013

Cited by 34 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Continuous infusion of vancomycin may be a solution to this problem. In addition, newer antibacterials such as linezolid, tigecycline, ertapenem, and moxifloxacin are also promising, and have demonstrated non-inferiority in several studies of IAI[40,92-95]. …”

Section: Antibiotic Therapymentioning

confidence: 99%

A Comprehensive review of abdominal infections

Lopez¹,

Kobayashi

Coimbra

2011

World J Emerg Surg

View full text Add to dashboard Cite

Section: Antibiotic Therapymentioning

confidence: 99%

A Comprehensive review of abdominal infections

Lopez¹,

Kobayashi

Coimbra

2011

World J Emerg Surg

View full text Add to dashboard Cite

“…In fact in several clinical trials comparing different therapeutic options inclusion/exclusion of agents with enterococcal coverage provides no impact in outcomes for patients with community-acquired infections [178,179]. …”

Section: Extra-biliary Community-acquired Intra-abdominal Infectionsmentioning

confidence: 99%

WSES consensus conference: Guidelines for first-line management of intra-abdominal infections

et al. 2011

View full text Add to dashboard Cite

Intra-abdominal infections are still associated with high rate of morbidity and mortality.A multidisciplinary approach to the management of patients with intra-abdominal infections may be an important factor in the quality of care. The presence of a team of health professionals from various disciplines, working in concert, may improve efficiency, outcome, and the cost of care.A World Society of Emergency Surgery (WSES) Consensus Conference was held in Bologna on July 2010, during the 1st congress of the WSES, involving surgeons, infectious disease specialists, pharmacologists, radiologists and intensivists with the goal of defining recommendations for the early management of intra-abdominal infections.This document represents the executive summary of the final guidelines approved by the consensus conference.

show abstract

“…Regarding the characteristics of the population of the included RCTs involving patients with cIAIs, it was specifically reported that patients with severe infections (APACHE II score > 30[11,12,14]) were excluded. Most of the trials only included patients infected with pathogens susceptible to study antimicrobial treatments or with at least one pathogen being susceptible to study treatments in the case of polymicrobial infections, and excluded the patients with infections caused by pathogens known to be resistant to study treatments.…”

Section: Resultsmentioning

confidence: 99%

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials

Zou

Shen

et al. 2009

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundErtapenem, a new carbapenem with a favorable pharmacokinetic profile, has been approved for the treatment of complicated intra-abdominal Infections (cIAIs), acute pelvic infections (APIs) and complicated skin and skin-structure infections (cSSSIs). The aim of this study is to compare the efficacy and safety of ertapenem with piperacillin/tazobactam, which has been reported to possess good efficacy for the treatment of these complicated infections.MethodsWe performed a meta-analysis of randomized controlled trials identified in PubMed, Cochrane library and Embase that compared the efficacy and safety of ertapenem with piperacillin/tazobactam for the treatment of complicated infections including cIAIs, APIs, cSSSIs. The primary efficacy outcome was clinical treatment success assessed at the test-of-cure visit. The primary safety outcome was drug related clinical and laboratory adverse events occurred during the treatment and the post-treatment period.ResultSix RCTs, involving 3161 patients, were included in our meta-analysis. Ertapenem was associated similar clinical treatment success with piperacillin/tazobactam for complicated infections treatment (clinically evaluable population, 1937 patients, odds ratios: 1.15, 95% confidence intervals: 0.89-1.49; modified intention to treat population, 2855 patients, odds ratios: 1.03, 95% confidence intervals: 0.87-1.22). All of secondary efficacy outcomes analysis obtained similar findings with clinical treatment success. No difference was found about the incidence of drug related adverse events between ertapenem and piperacillin/tazobactam groups.ConclusionThis meta-analysis provides evidence that ertapenem 1 g once a day can be used as effectively and safely as recommended dose of piperacillin/tazobactam, for the treatment of complicated infections, particularly of mild to moderate severity. It is an appealing option for the treatment of these complicated infections.

show abstract

Untitled

Cited by 34 publications

References 0 publications

A Comprehensive review of abdominal infections

A Comprehensive review of abdominal infections

WSES consensus conference: Guidelines for first-line management of intra-abdominal infections

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About